BioArctic

BioArctic FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BioArctic (BIOA B.ST) as of Sep 27, 2026 is 138.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 193.68 % — a change of -28.24% (lower).

FCF Conversion

138.98 %

YoY

-28.24%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BioArctic is 2026 138.98 % . FCF Conversion Rate (FCF/EBITDA) of BioArctic was 2025 193.68 % . It decreases by -28.24% lower compared to the previous year.

The BioArctic FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-53.54 SEK
Jan 1, 2019
366.12 SEK
Jan 1, 2020
152.98 SEK
Jan 1, 2021
120.92 SEK
Jan 1, 2022
397.07 SEK
Jan 1, 2023
131.84 SEK
Jan 1, 2024
193.68 SEK
Jan 1, 2025
138.98 SEK
The BioArctic FCF Conversion history
YEARFCF ConversionYoY
138.98 %-28.24%
193.68 %+46.90%
131.84 %-66.80%
397.07 %+228.38%
120.92 %-20.96%
152.98 %-58.22%
366.12 %-783.83%
-53.54 %-94.15%
-915.58 %-178.43%
1,167.36 %-331.29%
-504.72 %—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

FCF Conversion Rate (FCF/EBITDA) of BioArctic is 138.98 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of BioArctic changed from 193.68 % to 138.98 %, representing a -28.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BioArctic since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — BioArctic

All Key Metrics — BioArctic